Literature DB >> 32274532

[Retinal detachment after intravitreal ocriplasmin injection].

Michael Müller1, Frank Koch1, Pankaj Singh1, Thomas Kohnen2.   

Abstract

After an uneventful intravitreal injection (IVI) of Ocriplasmin in a patient with reduced visual acuity due to vitreomacular traction (VMT) and a small macular hole, retinal detachment occurred within a few days after the operation. Although retinal detachment is known as a risk factor of IVI this case is noteworthy: an excessive reaction occurred in the region of the vitreous body, which resulted in the development of severe traction on the retina leading to a posterior vitreous body detachment, retinal holes and complete retinal detachment. This possible complication should be discussed in the preoperative patient informed consent and the reason for this excessive reaction should be the subject of further investigations.

Entities:  

Keywords:  IVI; Jetrea; Vitrectomy; Vitreomacular traction (VMT); Vitreous body detachment

Mesh:

Substances:

Year:  2021        PMID: 32274532     DOI: 10.1007/s00347-020-01085-7

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN: 0941-293X            Impact factor:   1.059


  6 in total

1.  Enzymatic vitreolysis with ocriplasmin for vitreomacular traction and macular holes.

Authors:  Peter Stalmans; Matthew S Benz; Arnd Gandorfer; Anselm Kampik; Aniz Girach; Stephen Pakola; Julia A Haller
Journal:  N Engl J Med       Date:  2012-08-16       Impact factor: 91.245

2.  SAFETY PROFILE OF OCRIPLASMIN FOR SYMPTOMATIC VITREOMACULAR ADHESION: A Comprehensive Analysis of Premarketing and Postmarketing Experiences.

Authors:  Paul Hahn; Mina M Chung; Harry W Flynn; Suber S Huang; Judy E Kim; Tamer H Mahmoud; Srinivas R Sadda; Pravin U Dugel
Journal:  Retina       Date:  2015-06       Impact factor: 4.256

3.  Improvement in Patient-Reported Visual Function After Ocriplasmin for Vitreomacular Adhesion: Results of the Microplasmin for Intravitreous Injection-Traction Release Without Surgical Treatment (MIVI-TRUST) Trials.

Authors:  Rohit Varma; Julia A Haller; Peter K Kaiser
Journal:  JAMA Ophthalmol       Date:  2015-09       Impact factor: 7.389

Review 4.  Assessment of retinal alterations after intravitreal ocriplasmin with spectral-domain optical coherence tomography.

Authors:  Yuji Itoh; Peter K Kaiser; Rishi P Singh; Sunil K Srivastava; Justis P Ehlers
Journal:  Ophthalmology       Date:  2014-09-07       Impact factor: 12.079

5.  A retrospective cohort study in patients with tractional diseases of the vitreomacular interface (ReCoVit).

Authors:  Peter Stalmans
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-02-22       Impact factor: 3.117

6.  Assessment of Ocriplasmin Effects on the Vitreoretinal Compartment in Porcine and Human Model Systems.

Authors:  Bart Jonckx; Michael Porcu; Aurelie Candi; Isabelle Etienne; Philippe Barbeaux; Jean H M Feyen
Journal:  J Ophthalmol       Date:  2017-10-29       Impact factor: 1.909

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.